{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:51:43Z","timestamp":1791910303740,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.09.050","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:02:30Z","timestamp":1569916950000},"page":"6915-6921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile"],"prefix":"10.1016","volume":"37","author":[{"given":"R.","family":"Villena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bast\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Santolaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.050_b0005","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.09.050_b0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","article-title":"Clinical recognition of meningococcal disease in children and adolescents","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.09.050_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2018.00321","article-title":"Invasive meningococcal disease in the vaccine era","volume":"6","author":"Nadel","year":"2018","journal-title":"Front Pediatr"},{"issue":"30 Suppl 2","key":"10.1016\/j.vaccine.2019.09.050_b0020","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2019.09.050_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: Biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2019.09.050_b0030","unstructured":"Ministerio de Salud de Chile, Subsecretar\u00eda de Salud P\u00fablica, Departamento de Epidemiolog\u00eda. Circular B51 No8 2017: Vigilancia epidemiol\u00f3gica de casos sospechosos de Enfermedad Meningoc\u00f3cica (A.39) y medidas de control 2017 [accessed 23 August 2019]."},{"key":"10.1016\/j.vaccine.2019.09.050_b0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4067\/S0370-41062012000600002","article-title":"Historia y epidemiolog\u00eda del meningococo","volume":"83","author":"Wilhelm","year":"2012","journal-title":"Rev Chil Pediatr"},{"key":"10.1016\/j.vaccine.2019.09.050_b0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4067\/S0716-10182014000400001","article-title":"Laboratory surveillance for invasive meningococcal disease in Chile, 2006\u20132012","volume":"31","author":"Araya","year":"2014","journal-title":"Rev Chil Infectolog\u00eda"},{"key":"10.1016\/j.vaccine.2019.09.050_b0045","unstructured":"Gallegos D, Maldonado A, Caceres K, Seoane M. Situaci\u00f3n epidemiol\u00f3gica y cumplimiento de indicadores de la vigilancia de la enfermedad meningoc\u00f3cica. 2010. Available from : http:\/\/epi.minsal.cl\/revista-el-vigia\/ [accessed 13 March 2019]."},{"key":"10.1016\/j.vaccine.2019.09.050_b0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3201\/eid2102.140746","article-title":"Neisseria meningitidis ST-11 clonal complex, Chile, 2012","volume":"21","author":"Araya","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.050_b0055","first-page":"350","article-title":"Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012","volume":"30","author":"Moreno","year":"2013","journal-title":"Rev Chil Infectol"},{"key":"10.1016\/j.vaccine.2019.09.050_b0060","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4067\/S0034-98872013000800001","article-title":"Emergence of W135 meningococcal serogroup in Chile during 2012","volume":"141","author":"Valenzuela","year":"2013","journal-title":"Rev Med Chil"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.050_b0065","doi-asserted-by":"crossref","first-page":"e66006","DOI":"10.1371\/journal.pone.0066006","article-title":"Molecular characterization of invasive neisseria meningitidis strains isolated in Chile during 2010\u20132011","volume":"8","author":"Barra","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2019.09.050_b0070","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1017\/S0950268814001149","article-title":"Serogroup W meningococcal disease: Global spread and current affect on the Southern Cone in Latin America","volume":"142","author":"Abad","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2019.09.050_b0075","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.050_b0080","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease Annual Epidemiological Report for 2017. Stockholm: 2019. https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2017 [accessed 23 August 2019]."},{"issue":"147","key":"10.1016\/j.vaccine.2019.09.050_b0085","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4067\/S0034-98872019000600776","article-title":"Plan de acci\u00f3n nacional frente a la emergencia de la cepa W-135 responsable de Enfermedad Meningoc\u00f3cica Invasora en Chile, 2012\u20132013","volume":"2019","author":"Valenzuela","year":"2019","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.vaccine.2019.09.050_b0090","unstructured":"Ministerio de Salud de Chile. Decreto 57 DECRETA ALERTA SANITARIA Y OTORGA FACULTADES EXTRAORDINARIAS QUE INDICA. 16 Noviembre 2012 Available from: https:\/\/www.leychile.cl\/N?i=1045789&f=2012-11-16&p= [accessed 13 March 2019]."},{"key":"10.1016\/j.vaccine.2019.09.050_b0095","unstructured":"Ministerio de Salud de Chile. Decreto No 1201 EXENTO, DE 2013-Modificaci\u00f3n decreto no 6, de 2010, que dispone vacunaci\u00f3n obligatoria contra enfermedades inmunoprevenibles de la poblaci\u00f3n del pa\u00eds. Santiago, Chile: 2013. Available from: https:\/\/vacunas.minsal.cl\/wp-content\/uploads\/2018\/08\/DTO-1201-EXENTO_29-NOV-2013.pdf [accessed 13 March 2019]."},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.050_b0100","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): A case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"37","key":"10.1016\/j.vaccine.2019.09.050_b0105","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.050_b0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21645515.2015.1010885","article-title":"Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country","volume":"11","author":"Izquierdo","year":"2015","journal-title":"Hum Vaccines Immunother"},{"issue":"30 Suppl 2","key":"10.1016\/j.vaccine.2019.09.050_b0115","doi-asserted-by":"crossref","first-page":"B37","DOI":"10.1016\/j.vaccine.2011.12.074","article-title":"Meningococcal disease from the public health policy perspective","volume":"30","author":"Black","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.050_b0120","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/21645515.2018.1458175","article-title":"Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines","volume":"14","author":"Villena","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2019.09.050_b0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"40","key":"10.1016\/j.vaccine.2019.09.050_b0130","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"issue":"9431","key":"10.1016\/j.vaccine.2019.09.050_b0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.09.050_b0140","first-page":"1","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA\u2013TT) on serogroup A meningococcal meningitis and carriage in Chad : a community trial","volume":"6736","author":"Djingarey","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.09.050_b0145","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: The experience in England and Wales","volume":"27","author":"Ampbell","year":"2009","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2019.09.050_b0150","first-page":"1391","article-title":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"7","key":"10.1016\/j.vaccine.2019.09.050_b0155","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"16","key":"10.1016\/j.vaccine.2019.09.050_b0160","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.vaccine.2017.03.010","article-title":"Meningococcal Study Group. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil","volume":"35","author":"Andrade","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.050_b0165","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/21645515.2017.1415682","article-title":"Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil","volume":"14","author":"Evellyn do Macedo","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2019.09.050_b0170","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3201\/eid2307.160129","article-title":"Case\u2013control study of risk factors for meningococcal disease in Chile","volume":"23","author":"Olea","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"43","key":"10.1016\/j.vaccine.2019.09.050_b0175","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1016\/j.vaccine.2014.08.015","article-title":"Meningococcal carriage prevalence in university students, 1824 years of age in Santiago, Chile","volume":"32","author":"Rodriguez","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.050_b0180","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jiph.2015.12.011","article-title":"Prevalence of meningococcal carriage in children and adolescents aged 10-19 years in Chile in 2013","volume":"9","author":"D\u00edaz","year":"2016","journal-title":"J Infect Public Health"},{"issue":"9911","key":"10.1016\/j.vaccine.2019.09.050_b0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA\u2013TT) on serogroup A meningococcal meningitis and carriage in Chad\u202f: a community trial","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.050_b0190","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:47Z","timestamp":1759401287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":38,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19312599"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}